258 related articles for article (PubMed ID: 8517452)
1. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
[No Abstract] [Full Text] [Related]
2. MedWatch: the FDA medical products reporting program.
Rheinstein PH
Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
[No Abstract] [Full Text] [Related]
3. MedWatch: the new medical products reporting program.
Couig MP; Merkatz RB
Am J Nurs; 1993 Aug; 93(8):65-8. PubMed ID: 8256839
[No Abstract] [Full Text] [Related]
4. MEDWATCH: the new FDA medical products reporting program.
Kennedy DL
Respir Care; 1993 Oct; 38(10):1077-80. PubMed ID: 10145891
[No Abstract] [Full Text] [Related]
5. MedWatch. On lookout for medical product problems.
Ropp KL
FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
[No Abstract] [Full Text] [Related]
6. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
[TBL] [Abstract][Full Text] [Related]
7. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
8. MEDWatch: the new FDA medical products reporting program.
Kessler DA
Clin Pharm; 1993 Jul; 12(7):529-32. PubMed ID: 8354041
[No Abstract] [Full Text] [Related]
9. MedWatch. FDA's 'heads up' on medical product safety.
Henkel J
FDA Consum; 1998; 32(6):10-2, 15. PubMed ID: 9854445
[No Abstract] [Full Text] [Related]
10. MedWatch targets reporting of serious adverse events.
VanAmringe M
Jt Comm Perspect; 1993; 13(4):15. PubMed ID: 10129237
[No Abstract] [Full Text] [Related]
11. Vaccine adverse event reporting: the importance of follow-up.
Varricchio F
Expert Rev Vaccines; 2005 Aug; 4(4):445-8. PubMed ID: 16117700
[No Abstract] [Full Text] [Related]
12. Adverse drug reactions and reporting.
Witte R
Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
[No Abstract] [Full Text] [Related]
13. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
14. Expedited safety reporting requirements for human drug and biological products; correction--FDA. Final rule; correction.
Fed Regist; 1998 Mar; 63(58):14611-2. PubMed ID: 10177754
[TBL] [Abstract][Full Text] [Related]
15. MEDWatch: medical products reporting program.
Minarik PA
Clin Nurse Spec; 1994 Mar; 8(2):74, 68. PubMed ID: 7882246
[No Abstract] [Full Text] [Related]
16. Medical device vigilance at FDA.
Gross TP; Kessler LG
Stud Health Technol Inform; 1996; 28():17-24. PubMed ID: 10164091
[TBL] [Abstract][Full Text] [Related]
17. Improving the quality of adverse drug reaction reporting by 4th-year medical students.
Rosebraugh CJ; Tsong Y; Zhou F; Chen M; Mackey AC; Flowers C; Toyer D; Flockhart DA; Honig PK
Pharmacoepidemiol Drug Saf; 2003 Mar; 12(2):97-101. PubMed ID: 12642973
[TBL] [Abstract][Full Text] [Related]
18. MedWatch: the new medical products reporting program.
Couig MP
Crit Care Nurse; 1993 Aug; 13(4):13-7. PubMed ID: 8375176
[No Abstract] [Full Text] [Related]
19. Reporting of adverse drug events: a key to postmarketing drug safety.
Rheinstein PH
Am Fam Physician; 1992 Sep; 46(3):873-4. PubMed ID: 1514478
[No Abstract] [Full Text] [Related]
20. Safe Medical Devices Act of 1990: current hospital requirements and recommended actions.
Alder H
Healthc Facil Manag Ser; 1993 Sep; ():1-34. PubMed ID: 10132639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
